🟢 GeneDx is trading 4% up today after exceeding Q2 expectations, reaffirming guidance, and announcing online exome testing

GeneDx (WGS) is trading 4.01% up now at $81.00 after several significant announcements on August 11, 2026:

• The company reported Q2 2026 adjusted net income of $0.4 million, achieving profitability one quarter ahead of previous expectations.
• GeneDx reaffirmed its full-year 2026 revenue guidance of $475 million to $490 million.
• A new online offering for clinician-guided exome testing was launched, designed to expand accessibility for eligible children with developmental delay, intellectual disability, or epilepsy.